?? ?Sugammadex Sodium (CAS 343306-79-6) - Product Overview?
Sugammadex Sodium is a ?synthetic γ-cyclodextrin derivative? (molecular formula: ?C??H???Na?O??S??, MW: 2178.01) designed to rapidly reverse ?rocuronium- or vecuronium-induced neuromuscular blockade? during surgical anesthesia. It acts as a selective ?neuromuscular reversal agent?, binding tightly to muscle relaxants to enable swift recovery of muscle function and reduce postoperative complications. With ≥99.5% HPLC purity and stability at ?2-8°C?, it is a critical pharmaceutical-grade API for anesthesia management.

?? ?Key Advantages?
?? ?Rapid Recovery?: Achieves neuromuscular recovery in ?≤3.6 minutes? with a 2.5 mg/kg dose.
?? ?High Selectivity?: Specifically targets rocuronium/vecuronium without affecting acetylcholine levels.
?? ?Water Solubility?: >50 mg/mL, ideal for injectable formulations.
?? ?Stability?: Maintains integrity under inert atmospheric storage conditions.

?? ?Applications?

• ?Surgical Anesthesia?: Primary use for reversing neuromuscular blockade post-surgery.

• ?Clinical Antidote?: Essential for emergency reversal of muscle relaxants.

• ?Research?: Studies on neuromuscular physiology and anesthesia optimization.

?? ?Quality & Compliance?

• Complies with ?USP/EP? pharmacopeial standards.

• Rigorously tested via ?HPLC, GC, and NMR? for batch consistency.

• Manufactured under ?GMP? guidelines in ISO-certified facilities.

?? ?Market Insight?
The global neuromuscular blockade reversal market is projected to grow ?significantly by 2030?, driven by rising surgical volumes and demand for precision anesthesia solutions. Sugammadex Sodium remains a ?gold-standard agent? due to its efficacy and safety profile.